HLA-DQB1 Markers Associated with Human Immunodeficiency Virus Type I Disease Progression

Abstract

In a previous investigation, we demonstrated that certain human leukocyte antigens (HLA) may be associated with human immunodeficiency virus type I (HIV-1) infection or protection from infection among regional African Americans and Caucasians. We demonstrated that HLA-DQB 1*0605 was associated with a possible increased risk of susceptibility to infection in African Americans and that DQB 1*0602 was associated with a possible increased risk of infection in Caucasians. The present study was designed to demonstrate possible HLA associations with HIV-1 disease progression and AIDS in regional African American and Caucasian populations. To differentiate rapid from slow progressors, immune parameters of the HIV-1-positive patient population were monitored over a mean follow-up period of 23 ± 2 months for African Americans (n = 30) and 25 ± 5 months for Caucasians (n = 22). To determine significance, HLA allele frequencies among rapid progressors were compared to those of slow progressors, separated by race. Results were analyzed by χ² analysis, with Fisher’s exact test where applicable, linear logistic regression and Kaplan-Meier survival analysis. In the HIV-1-positive African American group, a better prognosis was associated with HLA-DQB 1*0602. In the HIV-1-positive Caucasian group, HLA-DQB 1*0302 was associated with rapid HIV disease progression, but no marker was associated with a more favorable prognosis.

Distribution of human chemokine (C‐X3‐C) receptor 1 (CX3CR1) gene polymorphisms and haplotypes of the CC chemokine receptor 5 (CCR5) promoter in Chinese people, and the effects of CCR5 haplotypes on CCR5 expression

“…, 1997; Kostrikis et al ., 1998), CCR5 −59029A (McDermott et al., 1998), CCR2– 64I (Smith et al., 1997; Kostrikis et al ., 1998), SDF1– 3′A (Winkler et al. , 1998), and certain alleles of HLA class I and class II (Winchester et al ., 1995; Achord et al ., 1997; Candore et al ., 1998; Carrington et al ., 1999), present in various ethnic groups, have also been reported, by numerous laboratories worldwide, to be associated with the disease progression of AIDS.…”

“…The rare mutation, CCR5m303, at the coding region, possesses the same capability of protecting humans from HIV infection (Quillent et al, 1998). Other genetic polymorphisms, such as CCR5− 59653T (Smith et al, 1997;Kostrikis et al, 1998), CCR5− 59029A (McDermott et al, 1998), CCR2-64I (Smith et al, 1997;Kostrikis et al, 1998), SDF1-3′A , and certain alleles of HLA class I and class II (Winchester et al, 1995;Achord et al, 1997;Candore et al, 1998;Carrington et al, 1999), present in various ethnic groups, have also been reported, by numerous laboratories worldwide, to be associated with the disease progression of AIDS.…”

HIV Pharmacogenomics

“…interferon, interleukins, and transrectly or indirectly with MHC molecules. [26,27,[72][73][74][75][76][77][78][79][80][81][82][83][84][85] Patients HIV-positive patients of pathogenic organisms could result in with the 8.1 ancestral haplotype have been reported to have an toxicity. ancestral 8.1 [HLA-A*1, (e.g.…”

“…[7,14,78,[85][86][87][88][89][90][91][92] such as ciclosporine, which is metabolized by the same pathways as PIs, is increased in Black patients (patients of African Ameri- While their use as pharmacogenomic markers.…”

Potential nuclease-based strategies for HIV gene therapy

“…In addition, host genetic factors also play a role in pathogenesis. It is known that both non-MHC (105,106) and MHC (107,108) genes influence HIV replication and progression to AIDS.…”